NUE Life Health operates a telemedicine mental wellness platform that combines psychedelic-assisted therapies with a graph database-driven app and a data-led ‘quantified self’ approach. Its core offering includes at-home ketamine therapy paired with music therapies and provider-facing tools. The company launched Nue.App and Nue.Portal in November 2021 as proprietary technologies serving patients and providers. NUE Life competes with Mindbloom and Field Trip Health, the latter of which has physical treatment centers. The $23M Series A will support expansion of services into New York and growth across existing markets in Florida, Texas, California, Colorado, and Washington State, with Georgia and Massachusetts slated for April and twenty additional states planned by year-end. The company has also bolstered its advisory board with Andrey Ostrovsky, MD, and Phil Wolfson, MD, to help develop its care program. Nue Life Health develops telemedicine therapies targeting brain health, cognitive longevity and psychiatric conditions. The company is building treatments for depression, anxiety, bipolar disorder and post-traumatic stress disorder. Led by CEO Juan Pablo Cappello and CTO Demian Bellumio, Nue Life currently operates in California, Texas and Florida. It raised $3.3M in funding and intends to use the proceeds to expand operations, accelerate development efforts and broaden its business reach. The company plans to rapidly expand across the United States. Named backers in the round include Jack Abraham, Shervin Pishevar, Martin Varsavsky, Jon Oringer, James Bailey and Christina Getty.

Total raised

$26M

Funding rounds

3

Latest round

Series A

Latest activity

Apr 2022